Silverarc Capital Management LLC Makes New $5.23 Million Investment in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)

Silverarc Capital Management LLC bought a new position in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Free Report) in the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor bought 124,388 shares of the biopharmaceutical company's stock, valued at approximately $5,233,000. Silverarc Capital Management LLC owned approximately 0.13% of Ultragenyx Pharmaceutical at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Van ECK Associates Corp boosted its stake in shares of Ultragenyx Pharmaceutical by 18.4% in the fourth quarter. Van ECK Associates Corp now owns 1,760 shares of the biopharmaceutical company's stock worth $74,000 after acquiring an additional 273 shares during the period. Wealth Enhancement Advisory Services LLC boosted its stake in Ultragenyx Pharmaceutical by 1.4% in the 4th quarter. Wealth Enhancement Advisory Services LLC now owns 22,047 shares of the biopharmaceutical company's stock worth $928,000 after purchasing an additional 294 shares during the period. Smartleaf Asset Management LLC raised its position in shares of Ultragenyx Pharmaceutical by 259.5% during the fourth quarter. Smartleaf Asset Management LLC now owns 683 shares of the biopharmaceutical company's stock valued at $29,000 after buying an additional 493 shares during the last quarter. Arizona State Retirement System lifted its holdings in shares of Ultragenyx Pharmaceutical by 2.4% in the fourth quarter. Arizona State Retirement System now owns 24,038 shares of the biopharmaceutical company's stock worth $1,011,000 after buying an additional 568 shares in the last quarter. Finally, Guggenheim Capital LLC boosted its position in shares of Ultragenyx Pharmaceutical by 1.5% during the fourth quarter. Guggenheim Capital LLC now owns 45,222 shares of the biopharmaceutical company's stock worth $1,902,000 after acquiring an additional 670 shares during the last quarter. 97.67% of the stock is currently owned by institutional investors.

Insider Transactions at Ultragenyx Pharmaceutical

In other Ultragenyx Pharmaceutical news, EVP Karah Herdman Parschauer sold 2,990 shares of Ultragenyx Pharmaceutical stock in a transaction on Thursday, February 27th. The shares were sold at an average price of $42.88, for a total value of $128,211.20. Following the completion of the transaction, the executive vice president now owns 54,991 shares of the company's stock, valued at approximately $2,358,014.08. The trade was a 5.16 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, CFO Howard Horn sold 1,785 shares of the firm's stock in a transaction dated Thursday, March 6th. The shares were sold at an average price of $40.40, for a total value of $72,114.00. Following the sale, the chief financial officer now owns 106,169 shares in the company, valued at $4,289,227.60. This trade represents a 1.65 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 124,643 shares of company stock worth $5,256,268 over the last quarter. 5.50% of the stock is currently owned by insiders.

Ultragenyx Pharmaceutical Stock Up 1.2 %

Shares of Ultragenyx Pharmaceutical stock traded up $0.45 on Friday, reaching $38.09. 575,372 shares of the stock were exchanged, compared to its average volume of 818,321. Ultragenyx Pharmaceutical Inc. has a twelve month low of $29.59 and a twelve month high of $60.37. The business has a 50 day moving average price of $37.79 and a two-hundred day moving average price of $43.68. The firm has a market capitalization of $3.58 billion, a price-to-earnings ratio of -6.01 and a beta of 0.61.

Ultragenyx Pharmaceutical (NASDAQ:RARE - Get Free Report) last released its quarterly earnings data on Thursday, February 13th. The biopharmaceutical company reported ($1.39) earnings per share for the quarter, missing analysts' consensus estimates of ($1.32) by ($0.07). Ultragenyx Pharmaceutical had a negative return on equity of 193.80% and a negative net margin of 101.60%. The business had revenue of $164.88 million during the quarter, compared to analyst estimates of $163.23 million. Research analysts forecast that Ultragenyx Pharmaceutical Inc. will post -5.18 EPS for the current year.

Wall Street Analysts Forecast Growth

RARE has been the subject of several research reports. Piper Sandler dropped their price objective on shares of Ultragenyx Pharmaceutical from $140.00 to $115.00 and set an "overweight" rating for the company in a report on Monday, March 17th. HC Wainwright reiterated a "buy" rating and issued a $95.00 price target on shares of Ultragenyx Pharmaceutical in a research report on Friday, February 14th. Cantor Fitzgerald restated an "overweight" rating and issued a $118.00 price target on shares of Ultragenyx Pharmaceutical in a research report on Wednesday, February 26th. Canaccord Genuity Group increased their target price on shares of Ultragenyx Pharmaceutical from $121.00 to $136.00 and gave the company a "buy" rating in a research note on Tuesday, February 18th. Finally, Wedbush reiterated a "neutral" rating and issued a $48.00 price target (up from $46.00) on shares of Ultragenyx Pharmaceutical in a report on Monday, January 13th. One research analyst has rated the stock with a hold rating and thirteen have assigned a buy rating to the company. According to data from MarketBeat, Ultragenyx Pharmaceutical currently has an average rating of "Moderate Buy" and a consensus price target of $92.79.

Ultragenyx Pharmaceutical Company Profile

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.